Market Overview

Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Share:
Related IDXX
Jim Cramer Weighs In On Fitbit, Qualcomm And More
IDEXX Labs Is 'Top Dog'
Related NEOG
Earnings Scheduled For September 19, 2017
Benzinga's Top Upgrades, Downgrades For July 14, 2017

Below are the top diagnostic substances stocks on the NASDAQ in terms of revenue estimate for the current year.

Analysts expect IDEXX Laboratories (NASDAQ: IDXX) to post revenue of $1.30 billion for the year ending December, 2012. IDEXX had $221.44 million in total cash for the latest quarter.

Neogen (NASDAQ: NEOG) is likely to post revenue of $205.21 million in the year ending May, 2013. Neogen's trailing-twelve-month operating margin is 19.11%.

Meridian Bioscience (NASDAQ: VIVO) is expected to report revenue of $189.80 million for the year ending September, 2013. Meridian Bioscience's trailing-twelve-month ROE is 23.73%.

Abaxis (NASDAQ: ABAX) may report revenue of $182.77 million in the year ending March, 2013. Abaxis' PEG ratio is 3.40.

Posted-In: Diagnostic Substances Industry Highest Revenue Estimates NASDAQ StocksTrading Ideas

 

Related Articles (ABAX + IDXX)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...